MetaCap

Immuneering (IMRX) vs Pyxis Oncology (PYXS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immuneering (IMRX) has outperformed Pyxis Oncology (PYXS) over the past year, losing 53.7% versus a loss of 62.3%. Over five years, IMRX leads with a -85.0% price change compared with -85.9% for PYXS. Immuneering is the larger company by market cap ($218.9 million vs $216.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMRX-53.70%PYXS-62.29%
+19%-32%-83%
Nov 21, 20251 yearNov 20, 2026
IMRX-86.40%PYXS-85.99%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMRX versus PYXS key metrics
MetricIMRXPYXS
Share price$3.38$1.81
Market cap$218.90M$216.49M
1-day change-2.03%+7.74%
YTD return-48.63%+57.39%
1-year return-53.70%-62.29%
5-year return-85.00%-85.90%
EPS (TTM)$-0.92$-1.27
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$13.86M
Revenue growth (YoY)—-14.17%
Net income (latest FY)$-56.02M$-79.62M
Gross margin—82.77%
Operating margin—-609.18%
Net margin—-574.55%
52-week high$8.48$5.55
52-week low$3.29$1.03
Distance from 52-week high-60.14%-67.39%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+402.96%+354.14%
Average volume747.66K1.06M
Shares outstanding64.76M119.61M
Employees6556
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Immuneering

IMRX stock →

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

About Pyxis Oncology

PYXS stock →

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

IMRX vs PYXS FAQ

Which is bigger, Immuneering or Pyxis Oncology?

Immuneering (IMRX) is larger, with a market capitalization of $218.90M compared with $216.49M for Pyxis Oncology (PYXS).

Which stock has performed better over the past year, IMRX or PYXS?

IMRX returned -53.70% over the past 12 months, compared with -62.29% for PYXS (price return, excluding dividends). Past performance does not predict future results.

Are Immuneering and Pyxis Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons